Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 260 (ZNF260) is a C2H2-type zinc finger transcription factor predicted to enable DNA-binding, especially targeting promoter regions for RNA polymerase II-driven transcription, and acts as a cofactor—particularly in cardiac tissue, where it functions as an effector in alpha1-adrenergic signaling and can cooperatively activate genes such as ANF/NPPA with GATA4, a cardiac regulator[1]. It is primarily localized in the cytosol and nucleoplasm and belongs to the broader family of zinc finger transcription factors, which are widely involved in sequence-specific DNA binding and modulation of gene expression[1][3]. There is no evidence from the search results that ZNF260 is currently a therapeutic target, nor are there known interacting drugs or disease roles directly attributed to this protein[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 260 (ZNF260).